Clinical Aspects of Immunogenicity to Biopharmaceuticals

  • Simona Malucchi
  • Antonio Bertolotto
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VIII)


Multiple Sclerosis Factor VIII Human Insulin Granulocyte Macrophage Colony Stimulate Factor Glatiramer Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albertsson-Wikland, K. 1987. Clinical trial with authentic recombinant somatotropin in Sweden and Finland. Acta Paediatr. Scand. (Suppl.) 331:28–34.Google Scholar
  2. Altman, J.J., Pehuet, M., Slama, G., and Tchoapoutsky, C. 1983. Three cases of allergic reaction to human insulin (Letter). Lancet 2:524.PubMedGoogle Scholar
  3. Andersen, O.O. 1973. Insulin antibody formation II: the influence of species difference and method of administration. Acta Endocrinol. 72:33–45.PubMedGoogle Scholar
  4. Antignani, A. and Youle, R.J. 2007. The cytokine, GM-CSF, can deliver BCL-XL as an extracellular fusion protein to protect cells from apoptosis and retain differential induction. J. Biol. Chem. 282(15):11246–11254.PubMedGoogle Scholar
  5. Antonelli, G., Simeoni, E., Bagnato, F., Pozzilli, C., Turriziani, O., Tesoro, R., Di Marco, P., Gasperini, C., Fieschi, C., and Dianzani, F. 1999. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J. Neurol. Sci. 168:131–136.PubMedGoogle Scholar
  6. Arnon, R. and Aharoni, R. 2004. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl. Acad. Sci. USA 101:14593–14598.PubMedGoogle Scholar
  7. Barranco, P. and Lopez-Serrano, M.C. 1998. General and epidemiological aspects of allergic drug reactions. Clin. Exp. Allergy 28(Suppl. 4):61–62.PubMedGoogle Scholar
  8. Bekisz, J., Schmeisser, H., Hernandez, J., Goldman, N.D., and Zoon, K.C. 2004. Human Interferons alpha, beta and omega. Growth Factors 22:243–251.PubMedGoogle Scholar
  9. Bellomi, F., Scagnolari, C., Tomassini, V., Gasperini, C., Paolillo, A., Pozzilli, C., and Antonelli, G. 2003. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J. Neurol. Sci. 215:3–8.PubMedGoogle Scholar
  10. Bennett, C.L., Luminari, S., Nissenson, A.R., Tallman, M.S., Klinge, S.A., McWilliams, N., McKoy, J.M., Kim, B., Lyons, E.A., Trifilio, S.M., Raisch, D.W., Evens, A.M., Kuzel, D.M., Schumock, G.T., Belknap, S.M., Locatelli, F., Rossert, J., and Casadevall, N. 2004. Pure red cell aplasia and epoetin therapy. N. Engl. J. Med. 351:1403–1408.PubMedGoogle Scholar
  11. Bergrem, H., Danielson, B.G., Eckardt, K.U., Kurtz, A., and Stridsberg, M. 1993. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer, C., Koch, K.M., and Sciqalla, P., (eds). Erythropoietin: Molecular Physiology and Clinical Application. Marcel Dekker, New York,pp. 265–275.Google Scholar
  12. Berman, E., Heller, G., Kempin, S., Gee, T., Tran, L.-L., and Clarkson, B. 1990. Incidence of response and long-term follow up in a patient with hairy cell leukemia treated with recombinant human interferon alfa-2a. Blood 75:839–845.PubMedGoogle Scholar
  13. Berson, S.A., Yalow, R.S., Bauman, A., Rothschild, M.A., and Newerly, K. 1956. Insulin-I-131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J. Clin. Invest. 35:170.PubMedGoogle Scholar
  14. Bertolotto, A., Gilli, F., Sala, A., Audano, L., Castello, A., Magliola, U., Melis, F., and Giordana, M.T. 2001. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative competitive- PCR method for MxA quantification. J. Immunol. Methods 256:141–152.PubMedGoogle Scholar
  15. Bertolotto, A., Gilli, F., Sala, A., Capobianco, M., Malucchi, S., Milano, E., Melis, F., Marnetto, F., Lindberg, R.L., Bottero, R., Di Sapio, A., and Giordana, M.T. 2003. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60:634–639.PubMedGoogle Scholar
  16. Bertolotto, A., Malucchi, S., Milano, E., Castello, A., Capobianco, M., and Mutani, R. 2000. Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 49:95–100.Google Scholar
  17. Bijvoet, A.G.A., Van Hirtum, H., Kroos, M.A., Van de Kamp, E.H., Schoneveld, O., Visser, P., Brakenhoff, J.P., Weggeman, M., van Corven, E.J., Van der Ploeg, A.T., and Reuser, A.J. 1999. Human α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum. Mol. Genet. 8:2145–2153.PubMedGoogle Scholar
  18. Blandford, R.L., Sewell, H., Sharp, P., and Hearnshaw, J.R. 1982. Generalized allergic reaction with synthetic human insulin (Comment–Letter). Lancet 2:1468.Google Scholar
  19. Bonetti, P., Diodati, G., Drago, C., Casarin, C., Scaccabarozzi, S., Realdi, G., Ruol, A., and Alberti, A. 1994. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J. Hepatol. 20:416–420.PubMedGoogle Scholar
  20. Bray, G.L., Gomperts, E.D., Courter, S., Gruppo, R., Gordon, E.M., Manco-Jonshon, M., Shapiro, A., Scheibel, E., White, G., and Lee, M. 1994. A multicentre study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemofilia A. Blood 83:2428–2435.PubMedGoogle Scholar
  21. Brenner, T., Arnon, R., Sela, M., Abramsky, O., Meiner, Z., Riven-Kreitman, R., Tarcik, N., and Teitelbaum, D. 2001. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone™. J. Neuroimmunol. 115:152–160.PubMedGoogle Scholar
  22. Bristol, A. 1993. Recombinant DNA derived insulin analogues as potentially useful therapeutic agents. Trends Biotechnol. 11:301–305.Google Scholar
  23. Carveth-Johnson, A.O., Mylvaganam, K., and Child, D.F. 1982. Generalised allergic reaction with synthetic human insulin (Letter). Lancet 2:1287.PubMedGoogle Scholar
  24. Casadevall, N. 2002. Antibodies against rHuEPO: native and recombinant. Nephrol. Dial. Transplant. 17(Suppl. 5):42–47.PubMedGoogle Scholar
  25. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., and Mayeux, P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469–475.PubMedGoogle Scholar
  26. Chance, R.E., Root, M.A., and Galloway, J.A. 1976. The immunogenicity of insulin preparations. Acta Endocrinol. Suppl. (Copenh) 205:185–198.Google Scholar
  27. Charak, B., Agah, R., and Mazumder, A. 1993. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 81:3474–3479.PubMedGoogle Scholar
  28. Chen, J.W., Frystyk, J., Lauritzen, T., and Christiansen, J.S. 2005. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes. Eur. J. Endocrinol. 153(6):907–913.PubMedGoogle Scholar
  29. Clanet, M., Radue, E.W., Kappos, L., Hartung, H.P., Hohlfeld, R., Sandberg-Wollheim, M., Kooijmans-Coutinho, M.F., Tsao, E.C., Sandrock, A.W., and European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. 2002. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507–1517.PubMedGoogle Scholar
  30. Comi, G., Filippi, M., and Wolinsky, J.S. 2001. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49:290–297.PubMedGoogle Scholar
  31. Davidson, J.K. and DeBra, D.W. 1978. Immunologic insulin resistance. Diabetes 27:307–318.PubMedGoogle Scholar
  32. Deckert, T. 1985. The immunogenicity of new insulins. Diabetes 34(Suppl. 2):94–96.PubMedGoogle Scholar
  33. Deisenhammer, F., Reindl, M., Harvey, J., Gasse, T., Dilitz, E., and Berger, T. 1999. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 62:1239–1243.Google Scholar
  34. Deleeuw, I., Delvigne, C., and Beckaert, J. 1982. Insulin allergy treated with human insulin (recombinant DNA). Diabetes Care 5(Suppl. 2):168–170.Google Scholar
  35. deShazo, R.D., Levinson, A.I., Boehm, T., Evans, R. III, and Waed, G. Jr. 1977. Severe persistent biphasic local (immediate and late) skin reactions to insulin. J. Allergy Clin. Immunol. 59:161–164.PubMedGoogle Scholar
  36. DeWitt, D.E. and Hirsch, I.B. 2003. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: a scientific review. JAMA 289:2254–2264.PubMedGoogle Scholar
  37. Dianzani, F., Antonelli, G., Amicucci, P., Cefaro, A., and Pintus, C. 1989. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients. J. Interferon Res. 9(Suppl. 1):S33–S36.PubMedGoogle Scholar
  38. Douglas, D.D., Rakela, J., Lin, H.J., Hollinger, F.B., Taswell, H.F., Czaja, A.J., Gross, J.B., Anderson, M.L., Parent, K., and Fleming, C.R. 1993. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig. Dis. Sci. 38:601–607.PubMedGoogle Scholar
  39. Eckardt, K.U. and Casadevall, N. 2003. Pure red cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant. 18:865–869.PubMedGoogle Scholar
  40. Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Gungor, T., Krackhardt, B., and Kornhuber, B. 1992. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594–598.PubMedGoogle Scholar
  41. Farina, C., Weber, M.S., Meinl, E., Wekerle, H., and Hohlfeld, R. 2005. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4:567–575.PubMedGoogle Scholar
  42. Fernandez, O., Guerrero, M., Mayorga, C., Munoz, L., Lean, A., Lugue, G., Hervas, M., Fernandez, V., Capdevila, A., and de Ramon, E. 2002. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J. Neurol. 249:1058–1062.PubMedGoogle Scholar
  43. Figlin, R.A.and Itri, L. 1988. Anti-interfeon antibodies: a perspective. Semin. Hematol. 25:9–15.PubMedGoogle Scholar
  44. Fineberg, S.E. 1994. Insulin allergy and insulin resistance. In: Lebovitz, H.E., (ed). Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association, Alexandria, Virginia,. pp. 178–184.Google Scholar
  45. Fineberg, S.E., Galloway, J.A., Fineberg, N.S., and Goldman J. 1983. Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Diabetes 32:592–599.PubMedGoogle Scholar
  46. Fineberg, S.E., Huang, J., Brunelle, R., Gulliya, K.S., and Anderson J.H. 2003. Effect of long-term exposure to insulin Lispro on the induction of antibody response in patients with type 1 or type 2 Diabetes. Diabetes Care 26:89–96.PubMedGoogle Scholar
  47. Fireman, P., Fineberg, S.E., and Galloway, J.A. 1982. Development of IgE antibodies to human (recombinant DNA) porcine, and bovine insulins in diabetic subjects. Diabetes Care 5(Suppl. 2):119–125.PubMedGoogle Scholar
  48. Francis, G.S., Rice, G.P., Alsop, J.C., and PRISMS Study Group. 2005. Interferon beta-1a in MS. Results following development of neutralizing antibodies in PRISMS. Neurol. 65:48–55.Google Scholar
  49. Freund, M., von Wussow, P., Diedrich, H., Eisert, R., link, H., Wilke, H., Buchholz, F., LeBlanc, S., Fonatsch, C., Deicher, H., and Poliwoda, H. 1989. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br. J. Haematol. 72:350–356.PubMedGoogle Scholar
  50. Frigerio, C., Aubry, M., and Gomez, F. 1997. Desensitization-resistant insulin allergy. Allergy 52:238–239.PubMedGoogle Scholar
  51. Frost, H. 2005. Antibody-mediated side effects of recombinant proteins. Toxicology 209:155–160.PubMedGoogle Scholar
  52. Garcia-Ortega, P., Knobel, H., and Miranda, A. 1984. Sensitization to human insulin (Letter). BMJ 288:1271.PubMedGoogle Scholar
  53. Gneiss, C., Reindl, M., Lutterotti, A., Ehling, R., Egg, R., Khalil, M., Berger, T., and Deisenhammer, F. 2004. Interferon beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult. Scler. 10:507–510.PubMedGoogle Scholar
  54. Goodbourn, S., Didcock, L., and Randall, R.E. 2000. Interferons: cells signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81:2341–2364.PubMedGoogle Scholar
  55. Gossain, V.V., Rouner, D.R., and Homak, K. 1985. Systemic allergy to human (recombinant DNA) insulin. Ann. Allergy 55:116–118.PubMedGoogle Scholar
  56. Grammer, L.C., Roberts, M., Buchanan, T.A., Fitzsimons, R., Metzger, B.E., and Patterson, R. 1987. Specificity of immunoglobulin E and immunoglobulin G against human (recombinant DNA) insulin in human insulin allergy and resistance. J. Lab. Clin. Med. 109:141–146.PubMedGoogle Scholar
  57. Gribben, J.G., Devereux, S., Thomas, N.S., Keim, M., Jones, H.M., Goldstone, A.H., and Linch, D.C. 1990. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335:434–437.PubMedGoogle Scholar
  58. Hanauer, L. and Batson, J.M. 1961. Anaphylactic shock following insulin injection. Diabetes 10:105–109.Google Scholar
  59. Hill, A.D., Redmond, H.P., Austin, O.M., Grace, P.A., and Bouchier-Hayes, D. 1993. Granulocyte-macrophage colony-stimulating factor inhibits tumor growth. Br. J. Surg. 80:1543–1546.PubMedGoogle Scholar
  60. Holliday, S.M. and Benfield, P. 1997. Interferon-b-1a. A Review of its pharmacological proprieties and therapeutic potential in multiple sclerosis. BioDrugs 8:317–330.PubMedGoogle Scholar
  61. Hooijberg, E., Sein, J.J., van den Berk P.C., Hart, A.A., van der Valk, M.A., Kast, W.M., Melief, C.J., and Hekman, A. 1995. Eradication of large human B-cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin-2. Cancer Res. 55:2627–2634.PubMedGoogle Scholar
  62. Ishibashi, O., Kobayashi, M., Maegawa, H., Watanabe, N., Takata, Y., Okuno, Y., and Shigeta, Y. 1986. Can insulin antibodies of diabetic patients distinguish human insulin from porcine insulin? Horm. Metab. Res. 18:470–472.PubMedGoogle Scholar
  63. Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, R.T., Salazar, A.M., Fisher, J.S., Goodkin, D.E., Granger, C.V., Simon, J.H., Alam, J.J., Bartoszak, D.M., Bourdette, D.N., Braiman, J., Brownscheidle, C.M., Coats, M.E., Cohan, S.L., Dougherty, D.S., Kinkel, R.P., Mass, M.K., Munschauer, F.E., Priore, R.L., Pullicino, P.M., Scherokman, B.J., and Whitham, R.H. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:285–294.PubMedGoogle Scholar
  64. Johnson, K.B., Brooks, B.R., Ford, C.C., Goodman, A., Guarnaccia, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Pruitt, A., Rose, J.W., Kachuck, N., and Wolinsky, J.S. 2000. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult. Scler. 6:255–266.PubMedGoogle Scholar
  65. Johnson, K.B., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Rose, J.W., and Schiffer, R.B. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurol. 45:1268–1276.Google Scholar
  66. Johnson, K.B., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Rose, J.W., Schiffer, R.B., Vollmer, T., Weiner, L.P., and Wolinsky, J.S. 1998. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701–708.PubMedGoogle Scholar
  67. Johnson, K.P., Ford, C.C., Lisak, R.P., and Wolinsky, J.S. 2005. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol. Scand. 111(1):42–47.PubMedGoogle Scholar
  68. Jones, G.J. and Itri, L.M. 1986. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 57:1709–1715.PubMedGoogle Scholar
  69. Kaplan, S.L., Underwood, L.E., August, G.P., Bell, J.J., Blethen, S.L., Blizzard, R.M., Brown, D.R., Foley, T.P., Hintz, R.L., and Hopwood, N.J. 1986. Clinical studies with recombinant-DNA-derived methionyl human growth hormone deficient children. Lancet 1:697–700.PubMedGoogle Scholar
  70. Kappos, L., Clanet, M., Sandberg-Wollheim, M., Radue, E.W., Hartung, H.P., Hohlfeld, R., Xu, J., Bennett, D., Sandrock, A., Goelz, S., and European Interferon beta-1a IM dose-Comparison Study Investigators. 2005. European interferon beta-1a IM dose-comparison study investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65:40–47.PubMedGoogle Scholar
  71. Khan, O.A. and Dhib-Jalbut, S.S. 1998. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are crossreactive. Neurology 51:1696–1702.Google Scholar
  72. Kishnani, P.S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W.L., Lesile, N., Levine, J., Spencer, C., McDonald, M., Li, J., Dumontier, J., Halberthal, M., Chien, Y.H., Hopkin, R., Vijayaraghavan, S., Gruskin, D., Bartholomew, D., van der Ploeg, A., Clancy, J.P., Parini, R., Morin, G., Beck, M., De la Gastine, G.S., Jokic, M., Thurberg, B., Richards, S., Bali, D., Davison, M., Worden, M.A., Chen, Y.T., and Wraith, J.E. 2007. Recombinant human acid (alpha)-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109.PubMedGoogle Scholar
  73. Klinge, L., Straub, V., Neudorf, U., Schaper, J., Bosbach, T., Gorlinger, K., Wallot, M., Richards, S., and Voit, T. 2005. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul. Disord. 15:24–31.PubMedGoogle Scholar
  74. Kracke, A., von Wussow, P., Al-Masri, A.N., Dalley, G., Windhagen, A., and Heidenreich, F. 2000. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 54:193–199.PubMedGoogle Scholar
  75. Kromminga, A. and Schellekens, H. 2005. Antibodies against erythropoietin and other protein-based therapeutics. An overview. Ann. NY Acad. Sci. 1050:257–265.PubMedGoogle Scholar
  76. Kumar, D. 1997. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 20:1357–1359.PubMedGoogle Scholar
  77. Kuter, D.J. 2000. Future directions with platelet growth factors. Semin. Hematol. 37:41–49.PubMedGoogle Scholar
  78. Kuter, D.J. 2007. New thrombopoietic growth factors. Blood 109:4607–4616.PubMedGoogle Scholar
  79. Lacroix-Desmazes, S., Bayry, J., Misra, N., Horn, M.P., Villard, S., Pashov, A., Stieltjes, N., d’Oiron, R., Saint-Remy, J.M., Hoebeke, J., Kazatchkine, M.D., Reinbolt, J., Mohanty, D., and Kaveri, S.V. 2002. The prevalence of proteolytic antibodies against factor VIII in Haemophilia A. N. Engl. J. Med. 346:662–667.PubMedGoogle Scholar
  80. Lahtela, J.T., Knip, M., Paul, R., Antone, J., and Salmi, J. 1997. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro: a case report. Diabetes Care 20:71–73.PubMedGoogle Scholar
  81. Lang, D.M., Alpern, M.B., Visintainer, P.F., and Smith, S.T. 1991. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann. Intern. Med. 115:270–276.PubMedGoogle Scholar
  82. Li, D.K., Zhao, J.G., Paty, D.W., and University of British Columbia MS/MRI Analysis Research Group, and the SPECTRIMS Study Group. 2001. Randomized controlled trial of interferon beta-1a in secondary progressive MS. MRI results. Neurology 56:1505–1513.Google Scholar
  83. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., and Kuter, D. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248.PubMedGoogle Scholar
  84. Locatelli, F., Aljama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K.U., Macdougall, I.C., Macleod, A., Horl, W.H., Wiecek, A., and Cameron, S. 2004. Erythropoiesis-stimulating agents and antibody-mediated pure red cell aplasia: where are we now and where do we go from here? Nephrol. Dial. Transplant. 19:288–293.PubMedGoogle Scholar
  85. Lok, A.S., Lai, C.L., and Leung, E.K. 1990. Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus-related chronic liver diseases. Hepatology 12:1266–1270.PubMedGoogle Scholar
  86. Lundin, K., Berger, L., Blomberg, F., and Wilton, P. 1991. Development of anti-hGH antibodies during therapy with authentic human growth hormone. Acta Paediatr. Scand. 372:167–168.Google Scholar
  87. Lusher, J.M. 2000. Inhibitor antibodies to factor VIII and factor IX: management. Semin. Thromb. Hemost. 26:179–188.PubMedGoogle Scholar
  88. Lusher, J.M., Arkin, S., Abildgaard, C.F., and Schwartz, R.S. 1993. Recombinat factor VIII for the treatment of previously untreated patients with haemophilia A. safety, efficacy, and development of inhibitors. N. Engl. J. Med. 328:453–459.PubMedGoogle Scholar
  89. Malucchi, S., Capobianco, M., Gilli, F., Marnetto, F., Caldano, M., Sala, A., and Bertolotto, A. 2005. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. Neurol. Sci. 26:S213–S214.PubMedGoogle Scholar
  90. Malucchi, S., Sala, A., Gilli, F., Bottero, R., Di Sapio, A., Capobianco, M., and Bertolotto, A. 2004. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurol. 62:2031–2037.Google Scholar
  91. Mark, D.F., Lu, S.D., Creasey, A.A., Yamamoto, R., and Lin, L.S. 1984. Site-specific mutagene of the human fibroblast interferon gene. Proc. Natl. Acad. Sci. USA 81:5662–5666.PubMedGoogle Scholar
  92. Marshall, M.O., Heding, L.G., Villumsen, J., Akerblom, H.K., Baevre, H., Dahlguist, G., Kiaergaard, J.J., Knip, M., Lindgren, F., and Ludvigsson, J. 1988. Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res. 9:169–175.PubMedGoogle Scholar
  93. Massa, G., Vanderschueren-Lodeweyckx, M., and Bouillon, R. 1993. Five-year follow up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin. Endocrinol. 38:137–142.Google Scholar
  94. Masucci, G., Wersall, P., Raghnammar, P., and Mellstedt, H. 1989. Granulocyte monocyte colony stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 29:288–292.PubMedGoogle Scholar
  95. Mellstedt, H. 1994. Induction of anti-granulocyte-macrophage colony-stimulating factor antibodies against exogenous nonglycosylated GM-CSF: biological implications. J. Inteferon. Res. 14:179–180.Google Scholar
  96. Nguyen, K.B., Salazar-Mather, T.P., Dalod, M.Y., Van Deusen, J.B., Wei, X.O., Liew, F.Y., Caligiuri, M.A., Durbin, J.E., and Biron, C.A. 2002. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 69:4279–4287.Google Scholar
  97. Okada, Y., Taira, K., Takano, K., and Hizuka, N. 1987. A case report of growth attenuation during methionyl human growth hormone treatment. Endocrinol. Jpn. 34:621–626.PubMedGoogle Scholar
  98. Opdenakker, G., Van den Steen, P.E., Laureys, G., Hunninck, K., and Arnold, B. 2003. Neutralizing antibodies in gene-defective hosts. Trends Immunol. 24:94–100.PubMedGoogle Scholar
  99. Peces, R., de la Torre, M., Alcazar, R., and Urra, J.M. 1996. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anaemia. N. Engl. J. Med. 335:523–524.PubMedGoogle Scholar
  100. Pestka, S., Krause, C.D., and Walter, M.R. 2004. Interferons, interferon-like cytokines and their receptors. Immunol. Rev. 202:8–32.PubMedGoogle Scholar
  101. Peters, A., Klose, O., Hefty, R., Keck, F., and Kerner, W. 1995. The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. Diabet Med. 12:925–930.PubMedGoogle Scholar
  102. Petersen, B., Bendtzen, C., Koch-Henriksen, N., Ravnborg, M., Ross, C., Sorensen, P.S., and Danish Multiple Sclerosis Group. 2006. Persistence of neutralizing antibodies after discontinuation of IFNb therapy in patients with remitting-relapsing multiple sclerosis. Mult. Scler. 12:247–252.PubMedGoogle Scholar
  103. Petersen, B., Bendtzen, K., Koch-Henriksen, N., Ravnborg, M., Ross, C., Sorensen, P.S., and Danish Multiple Sclerosis Study Group. 2006. Persistence of neutralizing antibodies after discontinuation of IFNb therapy in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 12:247–252.Google Scholar
  104. Petros, W.P., Rabinowitz, J., Stuart, A.R., Gilbert, C.J., Kanakura, Y., Griffin, J.D., and Peters, W.P. 1992. Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support. Blood 80:1135–1140.PubMedGoogle Scholar
  105. Polman, C., Kappos, L., White, R., Dahlke, F., Beckmann, K., Pozzilli, C., Thompson, A., Petkau, J., Miller, D., and European Study Group in Interferon Beta-1b in Secondary Progressive MS. 2003. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurol. 60:37–43.Google Scholar
  106. Polman, C.H., O’Connor, P.W., Havrdova, E., Huthchinson, M., Kappos, L., Miller, D.H., Philips, J.T., Lublin, F.D., Giovannoni, G., Waigt, A., Toal, M., Lynn, F., Panzara, M.A., Sandrock, A.W., and the AFFIRM Investigators. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899–910.PubMedGoogle Scholar
  107. Pozzilli, C., Antonimi, G., Bagnato, F., Mainero, C., Tomassini, V., Onesti, E., Fantozzi, R., Galgani, S., Pasqualetti, P., Millefiorini, E., Spadaro, M., Dahlke, F., and Gasperini, C. 2002. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1b: a randomized trial in multiple sclerosis. J. Neurol. 249:50–56.PubMedGoogle Scholar
  108. Prabhakar, S.S. and Muhlfelder, T. 1997. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrol. 47:331–335.PubMedGoogle Scholar
  109. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498–1504.Google Scholar
  110. PRISMS-Study Group and the University of British Columbia MS/MRI Analysis Group. 2001. PRISMS-4. Long term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628–1636.Google Scholar
  111. Quesada, J.R., Rios, A., Swanson, D., Trown, P., and Gutterman, J.U. 1985. Antitumor activity of recombinant derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 3:1522–1528.PubMedGoogle Scholar
  112. Ragnhammar, P., Frodin, J.E., Trotta, P.P., and Mellstedt, H. 1994a. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol. Immunother. 39:254–262.Google Scholar
  113. Ragnhammar, P., Friesen, H.J., Frodin, J.E., Lefvert, A.K., Hassan, M., Osterborg, A., and Mellstedt, H. 1994b. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in non-immunocompromised patients. Blood 84:4078–4087.Google Scholar
  114. Rauschka, H., Farina, C., Sator, P., Gudek, S., Breier, F., and Schmidbauer, M. 2005. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology 64:1481–1482.PubMedGoogle Scholar
  115. Reeves, W.G. and Kelly, U. 1982. Insulin antibodies induced by bovine insulin therapy. Clin. Exp. Immunol. 50:163–170.PubMedGoogle Scholar
  116. Riedl, M.A. and Casillas, A.M. 2003. Adverse drug reactions: types and treatment options. Am. Fam. Physician 68:1781–1790.PubMedGoogle Scholar
  117. Rini, B., Wadhwa, M., Bird, C., Small, E., Gaines-Das, R., and Thorpe, R. 2005. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine 29:56–66.PubMedGoogle Scholar
  118. Rudick, R.A., Simonian, N.A., Alam, J.A., Campion, M., Scaramucci, J.O., Jones, W., Coats, M.E., Goodkin, D.E., Weinstock-Guttman, B., Herndon, R.M., Mass, M.K., Richert, J.R., Salazar, A.M., Munschauer, F.E., Cookfair, D.L., Simon, J.H., and Jacobs, L.B. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50:1266–1272.PubMedGoogle Scholar
  119. Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confraveux, C., Galetta, S.L., Radue, E.W., Lublin, F.D., Weinstock-Guttman, B., Wynn, D.R., Lynn, F., Panzara, M.A., Sandrock, A.W., and the SENTINEL Investigators, et al. 2006. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354:911–923.PubMedGoogle Scholar
  120. Runkel, L. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm. Res. 15:641–649.PubMedGoogle Scholar
  121. Salama, H.H., Hong, J., Zang, Y.C., El-Monqui, A., and Zhang, J. 2003. Blocking effects of serum reactive antibodies induced by galtiramer acetate treatment in multiple sclerosis. Brain 126:2638–2647.PubMedGoogle Scholar
  122. Sasaki, H., Bothner, B., Dell, A., and Fukuda, M. 1987. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem. 262:12059–12076.PubMedGoogle Scholar
  123. Schellekens, H. and Casadevall, N. 2004. Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 251(Suppl. 2):II4–II9.PubMedGoogle Scholar
  124. Schernthaner, G. 1993. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155–165.PubMedGoogle Scholar
  125. Skibelli, V., Nissen-Lie, G., and Torjesen, P. 2001. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98:3626–3634.Google Scholar
  126. Smith, L.F. 1966. Species variation in the amino acid sequence of insulin. Am. J. Med. 40:662–666.PubMedGoogle Scholar
  127. Sorensen, P.S., Deisenhammer, F., Dudac, P., Hohlfeld, R., Myhre, K.M., Palace, J., Polman, C., Pozzilli, C., and Ross, C. for the EFNS Task Force on Anti-IFN-b Antibodies in Multiple Sclerosis. 2005. Guidelines on use of anti-IFN antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-b antibodies in multiple sclerosis. Eur. J. Neurol. 12:817–827.PubMedGoogle Scholar
  128. Sorensen, P.S., Koch-Henriksen, N., Ross, C., Clemmesen, K.M., Bendtzen, K., and Danish Multiple Sclerosis Study Group. 2005. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65:33–39.PubMedGoogle Scholar
  129. Sorensen, P.S., Ross, C., Clemmesen, K.M., Bendtzen, K., Frederiksen, J.L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., Stenager, E., Koch-Henriksen, N., and the Danish Multiple Sclerosis Study Group. 2003. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184–1191.PubMedGoogle Scholar
  130. SPECTRIMS, Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon beta-1a in MS Study Group. 2001. Randomized controlled trial of interferon beta-1a in secondary progressive MS: clinical results. Neurology 56:1496–1504.Google Scholar
  131. Spiegel, R.J., Jacobs, S.L., and Treuhaft, M.W. 1989. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. J. Interferon. Res. 9(Suppl. 1):17–24.Google Scholar
  132. Steis, R.G., Smith, J.W., Urba, W.J., Clark, J.W., Itri, L.M., Evans, L.M., Schoenberger, C., and Longo, D.L. 1988. Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318:1409–1413.PubMedGoogle Scholar
  133. Takano, K., Shizume, K., and Hibi, I. 1989. Turner’s syndrome: treatment of 203 patients with recombinant human growth hormone for one year. A multicentre study. Acta Endocrinol. 120:559–568.PubMedGoogle Scholar
  134. Tangri, S., MothèB.R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., LiCalsi, C., and Sette, A. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol 174:3187–3196.PubMedGoogle Scholar
  135. Teitelbaum, D., Fridkis-Hareli, M., Arnon, S., and Sela, M. 1996. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:209–217.PubMedGoogle Scholar
  136. The IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661.Google Scholar
  137. The IFNβ MS Study Group and the University of British Columbia MS/MRI Analysis Group. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b:experiences during the first three years. Neurology 47:889–894.Google Scholar
  138. The IFNβ Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology 43:655–661.Google Scholar
  139. Tomassini, V., Paolillo, A., Russo, P., Giugni, E., Prosperini, L., Gasperini, C., Antonelli, G., Bastianello, S., and Pozzilli, C. 2006. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J. Neurol. 253:287–293.PubMedGoogle Scholar
  140. Ure, D.R. and Rodriguez, M. 2002. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J. 16:1260–1262.PubMedGoogle Scholar
  141. Vallittu, A.M., Halminen, M., Peltonieni, J., Ilonen, J., Julkunen, I., Salmi, A., Eralinna, J.P., and Finnish Beta-Interferon Study Group. 2002. Neutralizing antibodies reduce M×A protein induction in interferon-beta-1a-treated MS patients. Neurology 58:1786–1790.PubMedGoogle Scholar
  142. Van Haeften, T.W. 1989. Clinical significance of insulin antibodies in insulin-treated patients. Diabetes Care 9:641–648.Google Scholar
  143. Van Hove, J.L.K., Yang, H.W., and Wu, J.Y. 1996. High level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblast from patients with Pompe disease. Proc. Natl. Acad. Sci. USA 93:65–70.PubMedGoogle Scholar
  144. Velcovsky, H.G., Beringhoff, B., and Federlin, K. 1978. [Immediate type allergy to insulin (author’s translation)]. Immunitat und Infektion 6:146–152.PubMedGoogle Scholar
  145. Velcovsky, H.G. and Federlin, K.F. 1982. Insulin-specific IgG and IgE antibody response in type 1 diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care 5:126–128.PubMedGoogle Scholar
  146. Verhelst, D., Rossert, J., Casadevall, N., Kruger, A., Eckardt, K.U., and Macdougall, I.C. 2004. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363:1768–1771.PubMedGoogle Scholar
  147. von Wussow, P., Freund, M., Block, B., Diedrich, H., Poliwoda, H., and Deicher. H. 1987. Clinical significance of anti-IFN-a antibody titres during interferon therapy. Lancet 2:635–636.Google Scholar
  148. Wadhwa, M., Bird, C., Fagerberg, J., Gaines-Das, R., Ragnhammar, P., Mellstedt, H., and Thorpe, R. 1996. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 104:351–358.PubMedGoogle Scholar
  149. Walford, S., Allison, S.P., and Reeves, W.G. 1982. The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia 22:106–110.PubMedGoogle Scholar
  150. Walsh, G. 2004. Second-generation biopharmaceuticals. Eur. J. Pharm. Biopharm. 58:185–196.PubMedGoogle Scholar
  151. Walsh, G. 2005. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol. 553–558.Google Scholar
  152. Witters, L.A., Ohman, J.L., Weir, G.C., Raymond, L.W., and Lowell, F.C. 1977. Insulin antibodies in the pathogenesis of insulin allergy and resistance. Am. J. Med. 63:703–709.PubMedGoogle Scholar
  153. Wolinsky, J.S., Narayana, P.A., Johnson, K.B., and Multiple Sclerosis Study Group and the MRI Analysis Center. 2001. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult. Scler. 7:33–41.PubMedGoogle Scholar
  154. Yamamoto, K., Takamatsu, J., and Saito, H. 2007. Intavenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review. Int. J. Haematol. 85:287–293.Google Scholar
  155. Zinman, L., Ng, E., and Bril, V. 2007. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837–841.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2008

Authors and Affiliations

  • Simona Malucchi
  • Antonio Bertolotto

There are no affiliations available

Personalised recommendations